Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Cancer Sci ; 102(2): 478-83, 2011 Feb.
Article in English | MEDLINE | ID: mdl-21143703

ABSTRACT

S-1 is an oral fluoropyrimidine anti-neoplastic agent that is converted by CYP2A6 to 5-fluorouracil (5FU). We prospectively studied the pharmacokinetics and pharmacodynamics of S-1 in two groups of East Asian and Caucasian patients with solid malignancy refractory to standard chemotherapy, or for which 5FU was indicated, to elucidate differences in relation to CYP2A6 genotype and phenotype. S-1 was given orally at 30 mg/m(2) b.i.d. for 14 days every 21 days. Dose normalized AUC(0-48 h) for tegafur (P = 0.05) and gimeracil (P = 0.036) were higher in East Asians; conversely, AUC(0-48 h) of fluoro-ß-alanine was higher in Caucasians (P = 0.044). Exposure to 5FU was similar in both groups (P = 0.967). Mean cotinine:nicotine ratio was 54% higher in the Caucasian group (P = 0.03), and correlated with oral clearance of tegafur (r = 0.59; P = 0.002). Grade 3/4 gastrointestinal toxicities were more common in Caucasians than Asians (21%vs 0%). Treatment with S-1 yields no significant difference in 5FU exposure between Caucasians and East Asians.


Subject(s)
Antimetabolites, Antineoplastic/pharmacokinetics , Oxonic Acid/pharmacokinetics , Tegafur/pharmacokinetics , Adult , Aged , Antimetabolites, Antineoplastic/adverse effects , Area Under Curve , Aryl Hydrocarbon Hydroxylases/genetics , Asian People/genetics , Cytochrome P-450 CYP2A6 , Drug Combinations , Asia, Eastern , Female , Genotype , Humans , Male , Middle Aged , Neoplasms/drug therapy , Oxonic Acid/adverse effects , Phenotype , Tegafur/adverse effects , White People/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...